NCT01427244View on ClinicalTrials.gov

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2015

Conditions

Paget's Disease of the Vulva

Interventions

DRUG

trastuzumab

monoclonal antibody

Trial Locations (1)

06520

Smilow Cancer Hospital at Yale New Haven, New Haven

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Yale University

OTHER